179 related articles for article (PubMed ID: 11363518)
1. Liposome battle for antifungal market shifts into high gear.
Marks S
J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):46-7. PubMed ID: 11363518
[TBL] [Abstract][Full Text] [Related]
2. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
3. The current role of amphotericin B lipid complex in managing systemic fungal infections.
Chu P; Sadullah S
Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324
[TBL] [Abstract][Full Text] [Related]
4. Focus on fungal infections.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1997 Jul; 3(7):27-32. PubMed ID: 11364470
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of amphotericin B in the treatment of invasive fungal infection in 111 hematological disorder patients with neutrocytopenia].
Tong HY; Zhang FJ; Xiao F; Qian WB; Meng HT; Mai WY; Tong Y; Mao LP; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):472-5. PubMed ID: 19035181
[TBL] [Abstract][Full Text] [Related]
6. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
7. The use of lipid formulations of amphotericin B for systemic fungal infections.
Leenders AC; de Marie S
Leukemia; 1996 Oct; 10(10):1570-5. PubMed ID: 8847891
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
9. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data.
Muñoz P; Guinea J; Narbona MT; Bouza E
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S125-31. PubMed ID: 19013336
[TBL] [Abstract][Full Text] [Related]
10. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
Clemons KV; Stevens DA
Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807
[TBL] [Abstract][Full Text] [Related]
12. [Choice and use of antifungal drugs].
Dupont B
Rev Prat; 2001 Apr; 51(7):752-7. PubMed ID: 11387672
[TBL] [Abstract][Full Text] [Related]
13. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
[TBL] [Abstract][Full Text] [Related]
14. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
Bellmann R; Cleary JD; Sterba J
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
[TBL] [Abstract][Full Text] [Related]
16. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
Metcalf SC; Dockrell DH
J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
[TBL] [Abstract][Full Text] [Related]
17. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
Cordonnier C; Bresnik M; Ebrahimi R
Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
[TBL] [Abstract][Full Text] [Related]
18. Management of systemic fungal infections: alternatives to itraconazole.
Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
[TBL] [Abstract][Full Text] [Related]
19. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B lipid preparations: what are the differences?
Adler-Moore JP; Proffitt RT
Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
